- Core Circadian Clock Genes Regulate Leukemia Stem CellsJune 14, 2016
Drs. Abdel-Wahab and Taylor look at a study about the use of core circadian clock genes in anti-leukemic therapy.
- Jedi T CellsJune 14, 2016 | Jonathan Hoggatt, PhD
Dr. Hoggatt looks at the Jedi mouse as a tool to advance hematology research.
- Understanding Immune Escape in Classical Hodgkin LymphomaJune 14, 2016 | Ann S. LaCasce, MD, MSc
Dr. LaCasce looks at understanding the use of checkpoint inhibitors to redirect the immune system to eliminate RS cells as an attractive therapeutic approach to classical Hodgkin lymphoma.
- Weighing the Pros and Cons of Dexamethasone Versus Prednisone in Childhood ALL InductionJune 14, 2016 | Elizabeth Raetz, MD
Dr. Raetz compares dexamethasone and prednisone for the induction phase of treatment of childhood acute lymphocytic leukemia.
- When Is a Negative Phase III Trial Positive in Sickle Cell Anemia?June 14, 2016 | Michael DeBaun, MD, MPH
Dr. DeBaun discusses a study for an antiplatelet agent with the goal of reducing the severity and frequency of severe, acute vaso-occlusive pain in SCD patients.
- Heparin-Induced Thrombocytopenia: A Preventable Nosocomial DiseaseJune 08, 2016 | Adam Cuker, MD, MS
Dr. Cuker studies options to reduce the incidence of HIT, treating it as a preventable nosocomial disease rather than an unavoidable iatrogenic disorder.
- Relapsed Multiple Myeloma: Now a Triad of Triplet CombinationsJune 03, 2016 | Paul Moss, PhD
Dr. Moss looks at three studies that show the success of three triplet combinations for the treatment of relapsed myeloma.
- Unique and Paradoxical Functions of the Tumor Suppressor PTENJune 03, 2016 | Theresa Coetzer, PhD
Dr. Coetzer studies the functions of the tumor suppressor PTEN as a new strategy to overcome drug resistance in human pre-B acute lymphoblastic leukemia.